*Supplemental table 2.* Adverse events after ERCP

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **All ERCP procedures (n=1991)** | **Planned bile duct cannulation with naïve papilla (n=1339)** | **Planned bile duct cannulation with previous sphincterotomy (n=499)** | **Planned pancreatic duct cannulation with naïve papilla (n=83)** | **Planned pancreatic duct cannulation with previous sphincterotomy (n=70)** | **p-value** |
| **Prevalence of AEs\*** | 304 (15.3%) | 15.7% | 11.0% | 21.7% | 30% | <0.001 |
|  |  |  |  |  |  |  |
| **PEP** | 150 (7.5%) | 7.5% | 3.6% | 18.1% | 24.3% | <0.001 |
| **Bleeding** | 26 (1.3%) | 1.6% | 0.8% | - | - | 0.242 |
| **Cholangitis** | 97 (4.9%) | 5.1% | 5.0% | 1.2% | 4.3% | 0.457 |
| **Cholecystitis** | 5 (0.3%) | 0.1% | 0.4% | 0% | 1.4% | 0.166 |
| **Other infection** | 25 (1.3%) | 1.3% | 0.8% | 3.6% | 1.4% | 0.206 |
| **Cardiac or pulmonary** | 18 (0.9%) | 1.2% | 0.4% | - | - | 0.254 |
| **Perforation** | 19 (1.0%) | 1.2% | 0.6% | - | - | 0.399 |
| **Total number of AEs** | 340 | 241 | 58 | 19 | 22 | - |
|  |  |  |  |  |  |  |
| **AE-related mortality** | 20 (1.0%) | 1.3% | 0.4% | 0% | 0% | 0.177 |

AE: adverse events; ERCP: endoscopic retrograde cholangiopancreatography

\* More than one adverse event may be present per procedure